Finviz chart – recent price action

After trading as a distressed micro-cap for most of 2024, PALI has re-rated aggressively in 2025 on the back of successive PALI-2108 readouts and a very large equity raise. The chart is now classic high-beta biotech: steep ramps into news, sharp pullbacks, and significant short interest overlay.

Source: Finviz daily chart (no recommendation implied). Open full chart on Finviz

Volumes are several million shares per day, with liquidity good for trading but fragile around catalysts. Position sizing and risk management are critical in names like this.

Executive summary – what PALI actually is

Palisade Bio today is essentially a single-program, single-platform bet on PALI-2108, an oral prodrug that delivers PDE4 B/D inhibition locally to the terminal ileum and colon for ulcerative colitis and fibrostenotic Crohn’s disease.

• Mechanism: PALI-2108 stays pharmacologically inert until it reaches the lower gut, where bacterial enzymes cleave the prodrug and release the active PDE4 inhibitor directly at the sites of inflammation and fibrosis. The goal is to maximise local efficacy while minimising systemic exposure and classic PDE4 side effects (nausea, headache, CNS effects).
• Data so far: In a tiny Phase 1b open-label UC cohort (n=5), PALI-2108 produced a 100% clinical response rate and 40% clinical remission, with consistent biomarker improvements and no serious adverse events. PK data suggest once-daily dosing is feasible with sustained local tissue levels.
• IBD positioning: If Phase 2 replicates these signals in larger controlled studies, PALI-2108 could emerge as a differentiated, non-immunosuppressive oral option in UC and a first-in-class approach for FSCD, a segment with essentially no approved targeted therapies.
• Balance sheet reset: After running with “going concern” language and low cash, Palisade has raised roughly US$ 138M gross in an October 2025 offering, at the price of heavy dilution. The new cash is intended to fund Phase 2 and broaden the PDE4 prodrug platform.

In plain terms: PALI is now a high-risk, high-potential early-stage IBD bet where the science looks interesting, the IP is tightening, the cash burn is funded for the next leg of development, and equity holders are compensated with extreme volatility and substantial dilution risk.

IP, positioning and the IBD competitive landscape

Intellectual property

PALI-2108 now benefits from a multi-regional IP wall:

• Japan: newly granted composition-of-matter patent (“Gut Microbiota-Activated PDE4 Inhibitor Prodrug”), base term to 2041 with potential regulatory extensions.
• China: composition-of-matter patent allowance with protection into the mid-2040s (subject to timelines and extensions).
• Europe: notice of grant from the European Patent Office for key PALI-2108 claims.

For a small company, composition-of-matter protection in major IBD markets matters: it supports long-dated value for any larger pharma partner and reduces the risk that a “fast-follower” PDE4 prodrug cannibalises the opportunity.

Where could PALI-2108 fit in IBD?

The UC and Crohn’s markets are large, crowded and heavily biologic-driven. Today’s main classes include anti-TNF, anti-integrin, anti-IL-23/IL-12, JAK inhibitors and S1P modulators, alongside generics like 5-ASA and steroids.

• UC: PALI-2108 is being positioned as a once-daily, non-immunosuppressive oral option that could sit either before biologics in a biomarker-selected subpopulation, or in combination with biologics as an add-on in refractory disease.
• FSCD: fibrostenotic Crohn’s disease has almost no specific targeted therapies; patients often cycle through biologics and ultimately require surgery. A locally acting anti-inflammatory/anti-fibrotic agent with convincing data would instantly attract attention, although the development path is more complex.

The main competitive risk is not another PDE4 prodrug today – it’s whether PALI-2108 can generate enough incremental benefit vs. existing oral and biologic options to justify premium pricing and guideline uptake.

Financial position, dilution and balance-sheet risk

From going concern…

Up to mid-2024, Palisade’s filings carried explicit “substantial doubt” language around its ability to continue as a going concern, with:

• Cash and equivalents of roughly US$ 11.4M as of 30 June 2024.
• Accumulated deficit of ~US$ 129M and ongoing operating losses.
• A business plan heavily dependent on additional equity raises and partnering.

…to a heavily diluted but funded story

The picture changed in 2H 2025:

• 30 Sep 2025 (pre-offering): cash down to ~US$ 5.2M, with modest quarterly burn but no capacity to fund Phase 2 alone.
• 2 Oct 2025: closing of an upsized underwritten public offering raising about US$ 138M in gross proceeds (including full over-allotment).
• Common shares outstanding surged to roughly 149M by early November 2025, meaning very significant dilution for legacy holders but a much stronger balance sheet for funding the next development stage.

Assuming spend broadly consistent with 2025 levels, that capital can in principle fund Phase 2 in UC and a meaningful FSCD program. In practice, spend is likely to step up as Phase 2 starts, and further raises later in the decade are still probable if the program moves towards Phase 3.

Capital structure & listing mechanics

• A 1-for-15 reverse split was executed in April 2024, and the 2025 proxy authorises another reverse split in the 1-for-5 to 1-for-50 range at the board’s discretion.
• Short interest is material (~9% of shares, >10% of float), and the float is concentrated enough to enable sharp squeeze-type moves around news and financing.

Net: financing risk has been partially reset by the October raise, but this remains a company that lives off the capital markets and can – and likely will – issue more equity if PALI-2108 advances. Any long-term view has to bake dilution into the mental model.

Management, clinical team and governance

CEO – J.D. Finley

J.D. Finley is both Chief Executive Officer and a long-time finance executive. He has played key roles in raising close to US$ 1B across different companies, including previous roles as CFO, CEO and investment banker. Earlier in his career he helped take MetroGolf public, co-founded a financing boutique (Proteus Capital Partners) and started out at Deloitte in tax and accounting.

The upside: a CEO who knows how to keep a small company financed and navigate complex capital markets. The downside: this is not a “bench scientist” or IBD-specialist founder; most of the scientific and clinical depth sits elsewhere in the org.

Clinical & translational leadership

• Mitch Jones, MD, PhD – President & Chief Medical Officer: extensive track record in inflammatory and fibrotic diseases, including roles at Chemomab, Finch Therapeutics and Biora (Progenity). Experience spans IBD programs, translational medicine and IPO-stage biotech work.
• Clinical operations / development leaders: Ryker Willie (SVP Finance & Controller), Sharon Skare (Global Head of Clinical Operations) and James Izanec (Head of Clinical Development), among others, bring a mix of GI and development experience.

Overall, the team looks competent for a Phase 1–2 shop, with particular strength on finance and GI drug development. For Phase 3 and commercial execution, a future partner or additional senior hires would almost certainly be needed.

Sentiment – Reddit, Stocktwits and X

PALI has become a favourite in several retail trading communities:

• Reddit: recurring threads in r/pennystocks and r/Daytrading frame PALI as a potential short-squeeze / value combo, pointing to a low float (pre-offering), high short interest and binary catalyst profile. The tone is upbeat but often speculative, with frequent references to large funds “pinning” or “walking” the price.
• Stocktwits: follower counts are rising and sentiment has swung to “extremely bullish” around major news (Phase 1b data, October offering, patent headlines), with message volume spikes in the tens-of-thousands-percent range in 24 hours.
• X (Twitter) and blogs: coverage is still niche but growing, often repeating the same talking points: 100% UC response in Phase 1b, huge addressable market, IP wins and the perceived potential for a take-out by a larger GI player if Phase 2 succeeds.

Scenarios – how this could realistically play out

1) Execution win – “data carry the stock”

• Phase 2 UC trial confirms robust remission and response rates in a biomarker-selected population, with tolerability clearly better than systemic PDE4 agents.
• FSCD data, even from small cohorts, show convincing anti-fibrotic signals and meaningful clinical benefit in a population with few alternatives.
• Palisade secures a regional or global development partner, de-risking Phase 3 funding and providing validation for the platform.

2) Mixed outcome – “science interesting, equity choppy”

• Phase 2 UC data show some activity but miss key endpoints (for example, remission rates that fail to beat best-in-class competitors), or benefit is limited to a narrow biomarker slice that is hard to commercialise.
• FSCD data are noisy or slow, making it difficult to build a clear label-defining package.
• The company continues as an independent small-cap, raising further capital on interim data and fighting dilution vs. upside in a typical “zig-zag” biotech trajectory.

3) Downside – “early-stage risk bites”

• Phase 2 programs fail to replicate the early UC signal, or safety issues emerge that undermine the gut-restricted narrative.
• FSCD proves too hard to capture with PALI-2108, either biologically or in terms of trial design.
• Without clear positive data, further capital becomes difficult or heavily dilutive, and the equity could re-rate sharply lower from current levels.

In all cases, this remains a binary, multi-year clinical story. Even in success, monetisation would depend on execution, partnering and the competitive response from established IBD players.

Risk map – key red flags to keep in mind

• Early-stage, single-asset exposure: virtually all value is tied to one program, PALI-2108, in early clinical development.
• Dilution and financing risk: the October 2025 raise has strengthened the balance sheet, but the business model still depends on future equity or partnering, especially if multiple Phase 2/3 programs are pursued in parallel.
• Clinical risk: Phase 1b UC data are promising but based on five open-label patients; Phase 2 may produce very different outcomes once larger, more heterogeneous populations are enrolled.
• Regulatory and endpoint risk: designing IBD trials that satisfy regulators and payers is complex (endpoints, histology, endoscopy, PROs, maintenance phases, etc.).
• Competition: multiple large pharma players are investing heavily in next-gen oral and biologic IBD therapies; if they deliver superior efficacy, a niche PDE4 prodrug will have to find its lane.
• Listing mechanics: history of reverse splits and a new reverse-split authorisation create ongoing technical risk for equity holders, especially if sentiment turns.